- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01633801
Use of High Flows in Pediatric Cardiac Surgical Patients
Use of High Flow Ventilation in Pediatric Cardiac Surgical Patients
Humidified high flow nasal prong oxygen therapy is a method for providing oxygen and CPAP. The delivery of high flows decreases dilution of the inhaled oxygen and, by matching patient's peak flow, allows accurate delivery of the set FiO2 throughout the whole inspiratory phase. In addition, a flow-dependent effect of continuous positive airway pressure, possibly due to an air entrainment mechanism, has been documented in healthy volunteers and in patients with COPD.
The investigators working hypothesis is that the use of post-extubation CPAP delivered via nasal cannulae in infants less than 18 months, post-bypass surgery will have better PaCO2 values than infants extubated on to oxygen therapy.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
After CICU admission, infants with no bleeding, normothermic and hemodynamically stable will be switched from PRVC to SIMV+PSV (10-15cmH20) which should be maintained for 4 hours. An arterial gas analysis will be performed after 20 minutes. Infants with normal gas-exchange are gradually weaned from mechanical ventilation At each weaning step an arterial hemogasanalysis is performed after 20 minutes, to assess if the decreased ventilatory support is tolerated. Increased work of breathing and respiratory acidosis (ph< 7.3 or pCO2 > 60 mmHg) are considered criteria to withhold the weaning process. After a 4 hour period on SIMV+PSV the child should be switched to PSV for 30 minutes and then extubated. The following extubation criteria should be reached:
- Satisfactory blood gases with PCO2 under 45mmHg, pH greater than 7.30.
- Fractional inspired oxygen concentration of 65% and or less than the baseline value
- Adequate respiratory frequency according to age without dyspnea
At this point criteria for extubation are reached. Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Rome, Italia, 00165
- Rekruttering
- Ospedale Bambino Gesu
-
Ta kontakt med:
- Francesca G Iodice, M.D.
- Telefonnummer: 2449 0039066859
- E-post: francesca_iodice@yahoo.it
-
Hovedetterforsker:
- Francesca Iodice, M.D.
-
Rome, Italia, 00195
- Rekruttering
- Francesca Iodice
-
Ta kontakt med:
- Francesca Iodice, MD
- Telefonnummer: 393336545045
- E-post: fgiovanna.iodice@opbg.net
-
Ta kontakt med:
- Francesca Iodice
- Telefonnummer: 393336545045
- E-post: francesca_iodice@yahoo.it
-
Underetterforsker:
- Giuseppina Testa, MD
-
Underetterforsker:
- Vincenzo Vitale, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age: 0-18 months
- Mechanical Ventilation via an endotracheal tube
- Elective surgery
- Post-bypass procedure
- Rachs 2 and above
Exclusion Criteria:
- Presence of major congenital malformations
- Presence of neuromuscular disease
- Presence of non drained pneumothorax
- Absent respiratory drive or recurrent apneas
- Hemodynamic instability
- Glasgow coma score (GCS) less than 8
- ECG with evidence of ischaemia or arrhythmias
- Active bleeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: High flows
|
Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
Andre navn:
Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
Andre navn:
|
Annen: oxygen therapy
|
Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The primary aim of this study is to show an improvement of the average levels of postextubation PaCO2 in infants less than 18 months of age and post-bypass surgery
Tidsramme: Final outcome measure is assessed when 80 patients have been recruited.Outcome measure is assessed at the end of 48 hours postextubation and when the patient is discharged from the ICU.
|
Final outcome measure is assessed when 80 patients have been recruited.Outcome measure is assessed at the end of 48 hours postextubation and when the patient is discharged from the ICU.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The secondary aim is to verify the reintubation rate between the two groups.
Tidsramme: Final outcome measure is assessed when 80 patients have been recruited.Outcome measure is assessed at the end of 48 hours postextubation and when the patient is discharged from the ICU.
|
Other points that will be evaluated are: the improvement of X-ray findings, the length of ICU stay and the development of complications such as nasal ulcers and gastric distension.
|
Final outcome measure is assessed when 80 patients have been recruited.Outcome measure is assessed at the end of 48 hours postextubation and when the patient is discharged from the ICU.
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Francesca Iodice, MD, Ospedale Bambino Gesu'
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- BambinoGHRI
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Medfødt hjertesykdom
-
Region SkanePåmelding etter invitasjonHjertesvikt New York Heart Association (NYHA) klasse II | Hjertesvikt New York Heart Association (NYHA) klasse IIISverige
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... og andre samarbeidspartnereHar ikke rekruttert ennåHjertesvikt, systolisk | Hjertesvikt med redusert utkastningsfraksjon | Hjertesvikt New York Heart Association Klasse IV | Hjertesvikt New York Heart Association klasse IIIPolen
-
Luigi Sacco University HospitalIRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Padova; Università degli Studi di Ferrara og andre samarbeidspartnereRekrutteringAtrieflimmer | Block Complete HeartItalia, Belgia, Sveits
-
University of WashingtonAmerican Heart AssociationFullførtHjertesvikt, Kongestiv | Mitokondriell endring | Hjertesvikt New York Heart Association Klasse IVForente stater
-
Novartis PharmaceuticalsFullførtPasienter som har fullført den 12-måneders behandlingsperioden i kjernestudien (de Novo Heart-mottakere) som var interessert i å bli behandlet med EC-MPS
-
University Hospital, GasthuisbergUkjentTransient Left Ventricular Ballooning SyndromeBelgia
-
NYU Langone HealthRekrutteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeForente stater
-
QLT Inc.FullførtLCA (Leber Congenital Amaurosis) | RP (Retinitis Pigmentosa)Forente stater, Canada, Tyskland, Nederland, Storbritannia
-
French Cardiology SocietyFullført
-
QLT Inc.FullførtLCA (Leber Congenital Amaurosis) | RP (Retinitis Pigmentosa)Canada, Forente stater, Tyskland, Nederland, Storbritannia